Holen Sie sich die Stockscreener-App
48.31
0.58%
0.28
Handel nachbörslich:
48.31
Schlusskurs vom Vortag:
$48.03
Offen:
$48.07
24-Stunden-Volumen:
809.70K
Relative Volume:
0.53
Marktkapitalisierung:
$3.85B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-12.88
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
-8.49%
1M Leistung:
-6.32%
6M Leistung:
-1.87%
1J Leistung:
+95.03%
1-Tages-Spanne:
$47.59
$48.78
1-Wochen-Bereich:
$47.10
$53.02
52-Wochen-Spanne:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
48.31 | 3.84B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Eingeleitet | TD Cowen | Buy |
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Akero Therapeutics COO Young sells $597k in shares - Investing.com
Akero Therapeutics CEO Cheng sells $1.46 million in stock - Investing.com
Aigen Investment Management LP Purchases Shares of 20,253 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Sentiment Turns Positive on Akero Therapeutics Inc. — Reversal AheadTrade Performance Summary & Weekly Momentum Picks - metal.it
Vivo Capital LLC Invests $8.14 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics director Henderson sells $142k in shares By Investing.com - Investing.com South Africa
Akero therapeutics director Henderson sells $142k in shares - Investing.com
Jefferies Financial Group Inc. Makes New $324,000 Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.8%Here's Why - MarketBeat
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year? - Yahoo Finance
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Buy" by Analysts - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 12,500 Shares of Stock - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Akero Therapeutics Inc. Hits Price Floor — Bounce IncomingAccurate Technical Trend Reversal Picks Detected - metal.it
Using Python tools to backtest Akero Therapeutics Inc. strategiesValue Investing Checklist with Entry Signals - Newser
Ranking Akero Therapeutics Inc. among high performing stocks via toolsFree AI Screening for Swing Trade Picks - Newser
Akari Therapeutics Reports Q2 EPS $(0.86) vs. $(0.81) Last Year - AInvest
Why Akero Therapeutics Inc. is moving todaySwing Reversal Forecast Based on Patterns - Newser
Can you recover from losses in Akero Therapeutics Inc.High Probability Trade Plan with Indicators - Newser
Is Akero Therapeutics Inc. building a consolidation baseHigh Reward Investment Strategy for Beginners - Newser
Published on: 2025-08-09 06:15:43 - beatles.ru
Akero Therapeutics Q2 Loss Narrows by 6%, EFX Clinical Trials Progress - AInvest
When is the best time to exit Akero Therapeutics Inc.Free AI-Powered Trade Planning with Indicators - Newser
Akero Therapeutics Advances in MASH Treatment Development - TipRanks
What MACD and RSI say about Akero Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Akero Therapeutics AKRO Q2 2025 Earnings Preview Upside Potential on Efruxifermin Advancements in MASH Treatment - AInvest
Ritu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position - TipRanks
Akero Therapeutics (NASDAQ:AKRO) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Akero Therapeutics Keeps Analysts Optimistic Despite Larger Losses - Finimize
Akero Therapeutics shares fall 1.31% intraday after Q2 net loss widens. - AInvest
Akero Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akero (AKRO) Q2 Loss Narrows 6% - Nasdaq
Akero Therapeutics' Q2 2025 Financial Results and Business Update: A Deep Dive into Metabolic Disease Innovation and Shareholder Value - AInvest
Akero Therapeutics Q2 Net Loss Widens - MarketScreener
Akero Therapeutics, Inc. SEC 10-Q Report - TradingView
Akero Therapeutics Q2 net income just shy of estimates, cash position strong - MarketScreener
Earnings Flash (AKRO) Akero Therapeutics Posts Q2 Net Loss $0.86 a Share, vs. FactSet Est of $0.96 Loss - MarketScreener
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
3 Top Artificial Intelligence (AI) Stocks Ready for a Bull Run - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Purchases New Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
When is the best time to buy Akero Therapeutics Inc. stockFree Community Shared Smart Money Signals - Newser
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - The Globe and Mail
Insider Selling at Akero Therapeutics: A Cautionary Signal Amidst Promising Clinical Progress - AInvest
Akero therapeutics CSO Rolph sells $616,299 in stock By Investing.com - Investing.com Canada
Allianz Asset Management GmbH Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Positioned as Leader in MASH Treatment with Efruxifermin Advancements - TipRanks
Morgan Stanley says zalfermin discontinuation has positive readthrough for Akero - TipRanks
Akero Therapeutics stock strengthened as Morgan Stanley reiterates Overweight rating - Investing.com Canada
TD Cowen Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - Defense World
Envestnet Asset Management Inc. Buys 3,170 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):